Detalles de la búsqueda
1.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576957
2.
Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.
J Oncol Pharm Pract
; 26(1): 13-22, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30832554
Resultados
1 -
2
de 2
1
Próxima >
>>